World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.
نویسندگان
چکیده
The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.
منابع مشابه
Has the rheumatoid arthritis (RA) core outcome set influenced the selection of study outcome measures?
Background The development and application of standardised sets of outcomes to be measured and reported in clinical trials have the potential to increase the efficiency and value of research. One of the most notable of the current outcome sets was developed nearly 20 years ago: the World Health Organisation (WHO) and International League of Associations for Rheumatology (ILAR) core set of outco...
متن کاملOutcome measures in rheumatoid arthritis randomised trials over the last 50 years
BACKGROUND The development and application of standardised sets of outcomes to be measured and reported in clinical trials have the potential to increase the efficiency and value of research. One of the most notable of the current outcome sets began nearly 20 years ago: the World Health Organization and International League of Associations for Rheumatology core set of outcomes for rheumatoid ar...
متن کاملTwenty‐Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register
OBJECTIVE To describe the outcome in patients with rheumatoid arthritis (RA) over 20 years from symptom onset, and to assess the association between early treatment (with disease-modifying antirheumatic drugs/steroids) and mortality and disability during follow-up. METHODS Patients recruited to the Norfolk Arthritis Register (NOAR) between 1990 and 1994 who met the 2010 American College of Rh...
متن کاملClinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial methodology to comment on the new draft 'Guideline on clinical investigation of medicinal products for the treatment of RA' released by the European Medicines Agency (EMA). Special emphasis was placed...
متن کاملSide effects and management of side effects of methotrexate in rheumatoid arthritis.
Low-dose methotrexate (MTX) remains the first-line treatment option among the disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. However, diverse side effects are the major reason for MTX withdrawal and change of treatment. The following article reviews the published data on general and organ-specific side effects and outlines the current recommendations addressing pre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of rheumatology. Supplement
دوره 41 شماره
صفحات -
تاریخ انتشار 1994